ClinicalTrials.gg
RecruitingNCT06418204COSMICUpdated Nov 4, 2026

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

An observational study in Breast Carcinoma, Colorectal Carcinoma and Lung Non-Small Cell Carcinoma, sponsored by Wake Forest University Health Sciences. Recruiting at 491 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Wake Forest University Health Sciences · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Nov 4, 2026Eligibility revised24 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Breast Neoplasms by Wake Forest University Health Sciences — 5 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Wake Forest University Health Sciences.

Planned enrollment
Largest of 18
2,000 · median 44
Started
2025
the only one that year
Observational
18 of 67
1 open now
Primary completion
2028-08
later than 6 of 11 live
Registered
64th of 67
by date

Among the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences, this one has the largest planned enrollment of the 18 observational ones that give a count, is the only one that started in 2025, is one of 18 observational ones, reaches primary completion later than 6 of the 11 other live ones, and was the 64th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Breast Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

Read the detailed description

The objective of this study is to examine the association between cannabis and/or cannabinoid use and cancer-related symptoms assessed monthly for one year in adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer who are planning or recently started to receive one or more systemic cancer directed therapies with chemotherapy and/or immune check point inhibitors (ICIs) targeting PD-1, PD-L1 or CTLA-4.

Participants complete surveys and have their medical records reviewed on study.

03

Conditions studied

  • Breast Carcinoma
  • Colorectal Carcinoma
  • Lung Non-Small Cell Carcinoma
  • Melanoma
  • Non-Hodgkin Lymphoma
04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or immune checkpoint inhibitors (ICIs)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified).
  • Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
  • Participants must be able to comprehend English or Spanish (for survey completion).
  • Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
  • Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.
  • Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey
  • In the treating provider's opinion, the participant should have a of >=6 months. Participants in hospice are not eligible.

Optional Sub-study (available at select sites only):

  • Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).
  • Must be receiving treatment at the WF CCC and VCU.
  • Must be planning to receive Immune Checkpoint Inhibitor (ICIs) targeting PD-1, PD-L1 or CTLA-4.

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms.
  • Participants with known pregnancy.
  • Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy.
  • Participants enrolled in hospice.

Optional Substudy (available at select sites only):

  • Participants with chronic or ongoing or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed.
  • Participants with a history of , or .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational

    Participants complete surveys and have their medical records reviewed on study.

    Other: Non-interventional Study

Interventions

  • OtherNon-interventional Study

    Non-interventional study

06

What researchers measure

Primary outcomes

  1. Cancer-related symptoms

    Will use the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to measure cancer-related symptoms. Will examine the longitudinal relationship between cannabis and/or cannabinoid use and the likelihood of exhibiting individual symptoms using three-level GLMMs to account for the nested data. The investigators will model continuous measures (e.g., symptom severity) using a linear generalized linear mixed-effects models (GLMM) and the prevalence of symptoms or moderate to severe symptoms using a logistic GLMM. Cannabis and/or cannabinoid use at each monthly assessment will be included as a time-varying covariate and an interaction with time will be included to assess its impact on symptoms over time. Analyses will consider dichotomous definitions of use (yes/no past month), frequency of use (# days in the past month) as well as mode of administration, dose/potency, and cannabinoid type.

    Time frame: Baseline and re-assessed monthly up to 12 months post-enrollment

Secondary outcomes

  1. Cannabis and Cannabinoid Use from Cannabis Engagement Assessment

    Cannabis and cannabinoid use will be measured monthly using items from the Cannabis Engagement Assessment (CEA). The CEA contains 30 questions that assess the quantity, frequency of use, and method of consumption for dried cannabis products (excluding edibles), cannabis concentrates, and edible products in the previous 30 days. Two additional sections assess other factors associated with cannabis use and history of use. Estimates of consumption can be calculated from responses, with a lower limit of 0 and no upper limit. Higher values represent higher consumption in that month.

    Time frame: Baseline and re-assessed monthly up to 12 months post-enrollment

  2. Cannabis and Cannabinoid Use from the International Cannabis Policy Study survey

    Cannabis and cannabinoid use will be measured monthly using items from the International Cannabis Policy Study (ICPS) survey. The ICPS surveys provide a comprehensive assessment of cannabis use, includes detailed patterns of consumption, purchasing, adverse outcomes, as well as attitudes and beliefs towards cannabis. Results from this survey will help quantify amount of cannabis use, if any.

    Time frame: Baseline and re-assessed monthly up to 12 months post-enrollment

  3. Cannabis and Cannabinoid Perceived Benefits and Harms

    The NCI Cannabis Core Measures survey will be used to ask cannabis and cannabinoid users each month whether they think cannabis or cannabinoid use worsened or improved their symptoms. Using the NCI Cannabis Core Measures survey, the investigators will ask cannabis and cannabinoid users each month whether they think cannabis or cannabinoid use worsened or improved their symptoms. The investigators will define this as a nominal outcome where 0=no change; 1=worsened quite a bit or somewhat worsened, and 2=somewhat improved or improved quite a bit.

    Time frame: Baseline and re-assessed monthly up to 12 months post-enrollment

  4. Cannabis and Cannabinoid Adverse Effects

    The Adverse Reactions Scale will be used to ask cannabis and cannabinoid users each month whether they have experienced a checklist of potential adverse reactions. The investigators will participants using cannabis and/or cannabinoids each month whether they have experienced a checklist of potential adverse reactions. These are defined as presence or absence of the adverse effect. The investigators will also consider the frequency of time they experience the effect (% of time they experience the effect when consuming cannabis or cannabinoids) and the severity of the effect (0 = Not at all distressing; 1 = Mildly distressing; 2 = Moderately distressing; 3 = Quite distressing 4 = Severely distressing) as continuous measures.

    Time frame: Baseline and re-assessed monthly up to 12 months post-enrollment

07

Study locations

491 of 491 sites recruiting

Showing the first 100 of 491 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Time frame: 6 months after publication for a 2 year duration

Access criteria: upon request to NCORP@wakehealth.edu

Data sharing details ↗ · nctn-data-archive.nci.nih.gov

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2028, 42 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 42 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
May 17, 2024
StartActual
Jan 30, 2025
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added
Show 24 added (24 United States)
  • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United States
  • Longmont United Hospital · Longmont, United States
  • Saint Mary Corwin Medical Center · Pueblo, United States
  • John B Amos Cancer Center · Columbus, United States
  • Minnesota Oncology Hematology PA-Chaska · Chaska, United States
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center · New York, United States
  • Upstate Cancer Center At Oswego · Oswego, United States
  • Upstate Cancer Center Radiation Oncology at Oswego · Oswego, United States
  • State University of New York Upstate Medical University · Syracuse, United States
  • SUNY Upstate Medical Center Community Campus · Syracuse, United States
  • James J Peters VA Medical Center · The Bronx, United States
  • Upstate Cancer Center at Verona · Verona, United States
  • Saint Elizabeth Boardman Hospital · Boardman, United States
  • Saint Joseph Warren Hospital · Warren, United States
  • MUSC Health Florence Medical Center · Florence, United States
  • MUSC Health Lancaster Medical Center · Lancaster, United States
  • MUSC Hematology-Oncology at Murrells Inlet · Murrells Inlet, United States
  • MUSC Health - Orangeburg · Orangeburg, United States
  • Sovah Health Martinsville · Martinsville, United States
  • John Muir Medical Center - Walnut Creek · Walnut Creek, United States
  • Fairview Cancer Center - Woodbury · Woodbury, United States
  • PeaceHealth Saint Joseph Medical Center · Bellingham, United States
  • Swedish Medical Center-Ballard Campus · Seattle, United States
  • PeaceHealth United General Medical Center · Sedro-Woolley, United States
across 2 updates, Oct 7, 2026 – Nov 4, 2026
Eligibility
1 inclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedMust be diagnosed with non-small cell lung cancer.
  • EditedMust be planning to receive paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) targeting PD-1, PD-L1 or CTLA-4.
Oct 7, 2026
Show all 2 updates
  1. Nov 4, 2026
    5 sites added
    Show 5 added (5 United States)
    • John Muir Medical Center - Walnut Creek · Walnut Creek, United States
    • Fairview Cancer Center - Woodbury · Woodbury, United States
    • PeaceHealth Saint Joseph Medical Center · Bellingham, United States
    • Swedish Medical Center-Ballard Campus · Seattle, United States
    • PeaceHealth United General Medical Center · Sedro-Woolley, United States
    + 1 other change: verification date
  2. Oct 7, 2026
    19 sites added
    Show 19 added (19 United States)
    • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United States
    • Longmont United Hospital · Longmont, United States
    • Saint Mary Corwin Medical Center · Pueblo, United States
    • John B Amos Cancer Center · Columbus, United States
    • Minnesota Oncology Hematology PA-Chaska · Chaska, United States
    • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center · New York, United States
    • Upstate Cancer Center At Oswego · Oswego, United States
    • Upstate Cancer Center Radiation Oncology at Oswego · Oswego, United States
    • State University of New York Upstate Medical University · Syracuse, United States
    • SUNY Upstate Medical Center Community Campus · Syracuse, United States
    • James J Peters VA Medical Center · The Bronx, United States
    • Upstate Cancer Center at Verona · Verona, United States
    • Saint Elizabeth Boardman Hospital · Boardman, United States
    • Saint Joseph Warren Hospital · Warren, United States
    • MUSC Health Florence Medical Center · Florence, United States
    • MUSC Health Lancaster Medical Center · Lancaster, United States
    • MUSC Hematology-Oncology at Murrells Inlet · Murrells Inlet, United States
    • MUSC Health - Orangeburg · Orangeburg, United States
    • Sovah Health Martinsville · Martinsville, United States
    Eligibility 1 inclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedMust be diagnosed with non-small cell lung cancer.
    • EditedMust be planning to receive paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) targeting PD-1, PD-L1 or CTLA-4.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06418204
Responsible party
Sponsor
First posted
May 17, 2024
Start date
Jan 30, 2025
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Karen Craver
Contact
NCORP@wfusm.edu
336-716-0891
Glenn Lesser, MD
study chair · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion